期刊文献+

ⅢB-T4期非小细胞肺癌141例预后因素分析 被引量:3

Prognostic analysis of non-small cell lung cancer at stage ⅢB-T4 among 141 patients
下载PDF
导出
摘要 目的对IIIB-T4期非小细胞肺癌(NSCLC)患者的预后相关因素进行探讨,比较干性IIIB期与湿性IIIB期患者生存相关因素及在预后方面的差异。方法回顾性分析未手术的IIIB-T4期NSCLC患者共141例。结果单因素分析表明患者的功能状态评分(ECOGPS)、淋巴结转移情况、治疗前血红蛋白、胸腔积液或(及)心包积液、白蛋白,化疗周期数与NSCLC患者生存期有关。干性IIIB期即未合并胸腔积液或(及)心包积液组患者中位生存时间为15.10个月,1年生存率为17%,湿性IIIB期即合并胸腔积液或/及心包积液组患者为8.27个月,1年生存率为11%(=0.013)。多因素分析显示ECOG PS评分、胸腔积液或/及心包积液、白蛋白,化疗周期数及对患者的生存有统计学意义(均<0.05)。结论湿性IIIB期即合并胸腔积液/心包积液是NSCLC患者差的预后表现。ECOG PS评分、白蛋白,化疗周期数是影响ⅢB-T4期NSCLC预后的相关因素。 Objective To investigate the prognostic factors in patients with non-small cell lung cancer(NSCLC) at stage IIIB-T4 and to compare survival related factors and difference of prognostic factors between dry IIIB and wet IIIB patients.Methods Retrospective study was carried on 183 patients who suffered from non-small cell lung cancer without operation Results Kaplan-Meier analysis showed that ECOG PS,lymph nodes status,hemoglobin before treatment,pleural effusion,pericardial effusion,albumin and chemotherapy periodicity were related to prognosis(P0.05).Patients with dry IIIB had a medium survival time of 15.10 months,and the survival rate of 1 year was 17%.Patients with wet IIIB had a median survival time of 8.27 months,and the survival rate of 1 year was 11%(P=0.013).Pleural effusion,pericardial effusion,albumin and chemotherapy periodicity in patients with unresectable NSCLC at stage IIIB were independent prognostic factors..Conclusions Pleural effusion/pericardial effusion is the poor prognostic factor in NSCLC.ECOG PS score,albumin and chemotherapy periodicity are the related factors which can impact the prognosis of NSCLC patients at stage ⅢB-T4.
作者 石荟 韩宝惠
机构地区 上海胸科医院
出处 《现代实用医学》 2011年第8期852-855,共4页 Modern Practical Medicine
关键词 非小细胞肺癌 ⅢB期 胸腔积液 预后 Non-small cell lung cancer Stage IIIB Pleural effusion Prognosis
  • 相关文献

参考文献8

  • 1钟南山,府军,束元珏.现代呼吸病进展[M].1版.北京:中国医药科技出版社,1994:416-431. 被引量:1
  • 2Groome PA, Bolejack V, Crowley JJ,et al. The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Ma- lignant Tumours[J]. Journal of Thoracic Oncology, 2007,2(8): 684-708. 被引量:1
  • 3Heys SD, Walker LG, Deehan DJ ,et al. Serum albumin:a progno- sitic indicator in patients with coloretal cancer[J]. J-R-Coll-Surg- Edinb, 1998,43(3):163-168. 被引量:1
  • 4Socinski MA, Zhang C, Hemdon JE 2nd, et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small- cell lung cancer: analysis of factors influencing survival and toxi- city[J]. Annals of Ontology ,2004,15(7): 1033 -1041. 被引量:1
  • 5Jett JR, Schild SE,Keith RL,et al. Treatment of non-small cell lung cancer, stage Ⅲ B: ACCP evidence-based clinical practice guidel- ines(2nd edition)[J]. Chest,2007,132(3 suppl):266S-277S. 被引量:1
  • 6Mountain CF.Revisions in the international system for staging lung cancer[J] .Chest, 1997,111 (6): 1710-1717. 被引量:1
  • 7Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non- small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol[J].J Clin Oncol,2005,23(25): 5883-5891. 被引量:1
  • 8Furuse K, Fukuoka M, Kowahara M, et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combina- tion with mitomycin, Vindesine, and cisplatin in unresctable stage Ⅲ non-small cell lung cancer[J].J Clin Oncol,1999,17(9): 2692-2699. 被引量:1

同被引文献48

  • 1陈尔成,刘孟忠,胡永红,李巧巧,刘慧,蔡玲,刘慧,林焕新,黄莹,王汉渝,崔念基.不能手术切除行同期放化疗的食管癌患者预后的多因素分析[J].癌症,2005,24(6):731-734. 被引量:38
  • 2王洲,刘相燕,陈钢,刘凡英.改良Ivor-Lewis手术对胸中段食管鳞癌治疗效果的评价[J].中国肿瘤临床,2006,33(17):1012-1015. 被引量:16
  • 3Alberg A J, Samet JM. Epidemiology of lung cancer [J]. Chest, 2003, 123 (suppl 1) : 21-49. 被引量:1
  • 4Jazich AR, Hussain M, Howington JA, et al. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer [J]. Ann Thorac Surg, 2000, 70 (4): 1168-1171. 被引量:1
  • 5Vargas SO, Leslie KO, Vacck PM, et al. Estrogen-re- ceptor-related protein p29 in primary non-small cell lung carcinoma pathologic and prognostic correlations [ J] Cancer, 1998, 82 (8): 1495-1500. 被引量:1
  • 6Visbal AL, MD, Williams BA, Nichols FC 3rd, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4, 618 patients diagnosed be- tween 1997 and 2002 [J] . Ann Thorac Surg, 2004, 78 (1) : 209-215. 被引量:1
  • 7Cerfolio R J, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung canc- er have better survival than men [J] . Chest, 2006, 130 (6): 1796-1802. 被引量:1
  • 8Janne PA, Gurubhagavatula S, Yeap BY, et al. Out- comes of patients with advanced non-small cell lung canc- er treated with gefitinib (ZD1839, 'Iressa' ) on an ex- panded access study [J] . Lung Cancer, 2004, 44 (2) : 221-230. 被引量:1
  • 9Keller SM, Vangel MG, Adak S, et al. The influence of gender on survival and tumor recurrence following adju- vant therapy of completely resected stages II and IIIa non- small cell lung cancer [J] . Lung Cancer, 2002, 37( 3 ) : 303-309. 被引量:1
  • 10Alexiou C, Onyeaka CV, Beggs D, et al. Do women live longer following lung resection for carcinoma? [ J~ . Eur J Cardio Thorac Surg, 2002, 21 (2) : 319 - 325. 被引量:1

引证文献3

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部